Table 2

Relationship between HOMA-IR index, others factors and CVD risk, univariable analysis

Variables	CVD risk with DAD equation		CVD risk with Framingham equation
Variables	Unadjusted β	p	Unadjusted β	p
HOMA-IR index	0.03	0.717	0.28	0.002
Socio-demographic characteristics
Occupation (employed/unemployed)	−0.08	0.105	−0.08	0.109
Education (secondary or high/primary or less)	−0.12	0.013	−0.10	0.042
Place of residence (urban/rural)	−0.01	0.868	−0.06	0.231
Physical activity (yes/no)	0.07	0.155	0.06	0.202
Hazardous alcohol consumption (yes/no)	0.03	0.513	−0.05	0.311
Clinical characteristics
Past history of CVD (yes/no)	/	/	0.04	0.463
Body mass index	0.01	0.9	0.15	0.002
Waist circumference	0.13	0.008	0.25	<0.001
Hip circumference	0.01	0.794	0.15	0.002
WHO clinical stages (3 or 4/1 or 2)	0.01	0.797	0.00	0.993
Duration of HIV infection	0.12	0.014	0.10	0.035
ART (yes/no)	/	/	0.01	0.783
ART line (second /first)	/	/	−0.07	0.193
ART duration	/	/	0.15	0.003
NRTIs (yes/no)	/	/	0.01	0.783
NNRTIs (yes/no)	/	/	0.05	0.287
PIs (yes/no)	/	/	−0.07	0.193
PI duration	/	/	0.21	0.294
Biological characteristics
Virus serotype (2 and 1+2/1)	0.01	0.726	−0.23	0.650
CD4 count	−0.04	0.507	0.01	0.853
Viral load (detectable/undetectable)	0.59	0.042	0.56	0.061
LDL-C	0.22	<0.001	0.28	<0.001
Triglycerides	0.09	0.059	0.10	0.043
Any dyslipidaemia (yes/no)	0.05	0.302	0.17	<0.001
Metabolic syndrome (yes/no)	0.03	0.481	0.31	<0.001

*β, Regression coefficient.
ART, antiretroviral therapy; CVD, cardiovascular disease; HOMA-IR, homeostasis model assessment of insulin resistance; LDL-C, low-density lipoprotein cholesterol; NNRT, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.